CA3024643C - Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy - Google Patents

Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy Download PDF

Info

Publication number
CA3024643C
CA3024643C CA3024643A CA3024643A CA3024643C CA 3024643 C CA3024643 C CA 3024643C CA 3024643 A CA3024643 A CA 3024643A CA 3024643 A CA3024643 A CA 3024643A CA 3024643 C CA3024643 C CA 3024643C
Authority
CA
Canada
Prior art keywords
biomarkers
expression
biomarker
extent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3024643A
Other languages
English (en)
French (fr)
Other versions
CA3024643A1 (en
Inventor
Robert T. Streeper
Sung H. Baek
Eizbieta Izbicka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Prevention and Cure Ltd
Original Assignee
Cancer Prevention and Cure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/403,369 external-priority patent/US8541183B2/en
Application filed by Cancer Prevention and Cure Ltd filed Critical Cancer Prevention and Cure Ltd
Publication of CA3024643A1 publication Critical patent/CA3024643A1/en
Application granted granted Critical
Publication of CA3024643C publication Critical patent/CA3024643C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3024643A 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy Active CA3024643C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/403,369 2009-03-12
US12/403,369 US8541183B2 (en) 2007-09-11 2009-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US23719809P 2009-08-26 2009-08-26
US61/237,198 2009-08-26
CA2755301A CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2755301A Division CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Publications (2)

Publication Number Publication Date
CA3024643A1 CA3024643A1 (en) 2010-09-16
CA3024643C true CA3024643C (en) 2021-08-03

Family

ID=42729154

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3024643A Active CA3024643C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
CA2755301A Active CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2755301A Active CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Country Status (10)

Country Link
US (1) US11474104B2 (enExample)
EP (4) EP2857522A3 (enExample)
JP (7) JP2012520469A (enExample)
KR (2) KR102061441B1 (enExample)
CN (4) CN104535765A (enExample)
AU (3) AU2010223911A1 (enExample)
CA (2) CA3024643C (enExample)
ES (1) ES2703714T3 (enExample)
PL (1) PL3257953T3 (enExample)
WO (1) WO2010105235A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2442919T3 (es) 2007-03-27 2014-02-14 Immunovia Ab Firma/marcadores de proteínas para la detección de adenocarcinoma
CA2834383A1 (en) * 2011-04-29 2012-11-01 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
JP2018532992A (ja) * 2015-09-09 2018-11-08 ソマロジック, インコーポレイテッドSomaLogic, Inc. 個別化薬物治療計画の開発方法、及びプロテオミックプロファイルに基づく標的薬物開発
WO2017043679A1 (en) * 2015-09-11 2017-03-16 Aptamer Sciences Inc. Protein biomarker panel for detecting non-small cell lung cancer and method for diagnosing a non-small cell lung cancer by the use thereof
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112501140B (zh) * 2020-12-16 2022-03-18 熊猫乳品集团股份有限公司 一种生物活性多肽yfgsgfaapffivrhqllkk及其制备方法和应用
TWI796010B (zh) * 2021-11-23 2023-03-11 國立高雄大學 基質金屬蛋白酶-1胜肽拓印導電聚合物及其用途
CN117907508A (zh) * 2023-12-19 2024-04-19 查理高特(青岛)健康科技有限公司 基于代谢组学的高尿酸血症及尿酸性肾病的风险预测系统

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0961780B1 (en) 1997-02-12 2007-04-11 Electrophoretics Limited Protein markers for lung cancer and use thereof
US20070092917A1 (en) 1998-05-01 2007-04-26 Isabelle Guyon Biomarkers for screening, predicting, and monitoring prostate disease
KR100704140B1 (ko) 1999-02-12 2007-04-09 더 스크립스 리서치 인스티튜트 혈관형성 억제제 및 항-종양 면역요법제를 포함하는, 종양 및 전이를 치료하기 위한 약제학적 조성물 및 이를 포함하는 키트
IL144559A0 (en) 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
FI990888A0 (fi) * 1999-04-20 1999-04-20 Medix Biochemica Ab Oy Menetelmä ja testikittejä respiratorisen alueen tulehduksen läsnäolon ja vaikeusasteen arvioimiseksi
WO2000065472A1 (en) * 1999-04-26 2000-11-02 Surromed, Inc. Phenotype and biological marker identification system
JP2004502453A (ja) 2000-07-12 2004-01-29 スミスクライン・ビーチャム・コーポレイション 新規化合物
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
EP1373896A2 (en) * 2001-03-12 2004-01-02 MonoGen, Inc. Cell-based detection and differentiation of disease states
DK1402073T3 (da) 2001-06-05 2007-06-11 Auckland Uniservices Ltd Fremgangsmåder og præparater til vurdering af lungefunktion og -lidelser
US20030134339A1 (en) 2002-01-14 2003-07-17 Thomas Brown Proteomics based method for toxicology testing
US20060088537A1 (en) 2002-04-11 2006-04-27 Terrett Jonathan A Protein involved in cancer
EP1575420A4 (en) 2002-05-10 2007-12-26 Eastern Virginia Med School PROSTATE CANCER-BIOMARKERS
AU2003240495A1 (en) * 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CN1854313B (zh) * 2002-09-30 2010-10-20 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
JP4723476B2 (ja) 2003-02-14 2011-07-13 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
KR20050106483A (ko) * 2003-03-04 2005-11-09 와이어쓰 천식 또는 그 밖의 알러지성 또는 염증성 질환을 진단 및치료하기 위한 조성물 및 방법
CN101265254A (zh) * 2003-03-27 2008-09-17 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
JP2005044330A (ja) 2003-07-24 2005-02-17 Univ Of California San Diego 弱仮説生成装置及び方法、学習装置及び方法、検出装置及び方法、表情学習装置及び方法、表情認識装置及び方法、並びにロボット装置
TW200600785A (en) 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
WO2005098445A2 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060084126A1 (en) * 2004-10-20 2006-04-20 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney and lung cancer
US20090297563A1 (en) * 2004-10-27 2009-12-03 Anders Borglum Diagnosis And Treatment of Immune-Related Diseases
EP1831684A4 (en) 2004-11-30 2009-03-11 Veridex Llc LUNGENKREBSPROGNOSTIK
CN1300580C (zh) 2004-12-31 2007-02-14 中国人民解放军第306医院 检测肝癌血清特征蛋白的质谱模型及其制备方法和应用
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
US20070099239A1 (en) 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US8053183B2 (en) * 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2618482C (en) * 2005-08-19 2014-10-07 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
WO2007026773A1 (ja) 2005-08-31 2007-03-08 Kurume University 医用診断処理装置
EP1941276A1 (de) 2005-10-29 2008-07-09 Bayer Technology Services GmbH Verfahren zur bestimmung eines oder mehrerer analyten in komplex zusammengesetzten proben biologischen ursprungs und dessen verwendung
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
KR100760518B1 (ko) 2006-07-18 2007-09-20 삼성정밀공업 주식회사 가구용 도어의 닫힘 충격 완충 장치
US7840505B2 (en) 2006-11-02 2010-11-23 George Mason Intellectual Properties, Inc. Classification tool
EP2087140A2 (en) * 2006-11-13 2009-08-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
WO2008077022A2 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Himf and btk in pulmonary, cardiac, and inflammation disorders
JP5085927B2 (ja) 2006-12-21 2012-11-28 ウィンテックポリマー株式会社 難燃性樹脂組成物
JP5385159B2 (ja) * 2007-02-28 2014-01-08 ノビミューン エスアー ヒト抗ｉｐ−１０抗体およびその使用
US20100088264A1 (en) 2007-04-05 2010-04-08 Aureon Laboratories Inc. Systems and methods for treating diagnosing and predicting the occurrence of a medical condition
WO2008144034A1 (en) 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
US20100272635A1 (en) 2007-06-15 2010-10-28 Rodems Kelline M Methods and compositions for diagnosis and/or prognosis in ovarian cancer and lung cancer
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US20090069189A1 (en) 2007-09-11 2009-03-12 Cancer Prevention And Cure, Ltd. Method of identifying proteins in human serum indicative of pathologies of human lung tissues
WO2009036123A1 (en) * 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
JP5159242B2 (ja) 2007-10-18 2013-03-06 キヤノン株式会社 診断支援装置、診断支援装置の制御方法、およびそのプログラム
WO2009074276A2 (en) 2007-12-10 2009-06-18 Roche Diagnostics Gmbh Marker panel for colorectal cancer
ES2809171T3 (es) 2008-01-18 2021-03-03 Harvard College Métodos para detectar distintivos de enfermedades o afecciones en fluidos corporales
EP2329260A4 (en) 2008-03-04 2011-08-03 Ridge Diagnostics Inc DIAGNOSIS AND MONITORING OF DEPRESSIVE DISORDERS BASED ON A PLURALITY OF BIOMARKER PANELS
CN101587125B (zh) 2008-05-21 2013-07-24 林标扬 高表达癌症标记物和低表达组织器官标记物组合试剂盒
SI2340506T1 (sl) 2008-09-09 2016-02-29 Somalogic, Inc. Biomarkerji za pljučni rak in njihove uporabe
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN101988059B (zh) 2009-07-30 2014-04-02 江苏命码生物科技有限公司 胃癌检测标记物及其检测试剂盒和生物芯片
GB2503148A (en) 2011-02-24 2013-12-18 Vermillion Inc Biomarker panels diagnostic methods and test kits for ovarian cancer
CA2834383A1 (en) 2011-04-29 2012-11-01 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2015066564A1 (en) 2013-10-31 2015-05-07 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2015138769A1 (en) 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer

Also Published As

Publication number Publication date
AU2010223911A1 (en) 2011-10-06
EP2857522A2 (en) 2015-04-08
EP2406401A4 (en) 2013-01-09
KR102061441B1 (ko) 2019-12-31
EP2406401A2 (en) 2012-01-18
AU2016228188A1 (en) 2016-09-29
JP2022000650A (ja) 2022-01-04
CA3024643A1 (en) 2010-09-16
JP2024024128A (ja) 2024-02-21
JP6774925B2 (ja) 2020-10-28
WO2010105235A2 (en) 2010-09-16
CN108181457A (zh) 2018-06-19
AU2018202110B2 (en) 2020-09-03
CN104535765A (zh) 2015-04-22
CA2755301A1 (en) 2010-09-16
ES2703714T3 (es) 2019-03-12
EP2857522A3 (en) 2015-10-14
JP2025114736A (ja) 2025-08-05
CN108181457B (zh) 2021-03-30
CN113189342A (zh) 2021-07-30
US11474104B2 (en) 2022-10-18
WO2010105235A3 (en) 2011-02-24
KR101900016B1 (ko) 2018-09-20
JP6250600B2 (ja) 2017-12-20
EP3444359A1 (en) 2019-02-20
KR20120010229A (ko) 2012-02-02
AU2018202110A1 (en) 2018-04-19
CN102405296A (zh) 2012-04-04
EP3257953A1 (en) 2017-12-20
CA2755301C (en) 2019-01-08
JP2018072348A (ja) 2018-05-10
PL3257953T3 (pl) 2019-05-31
JP2019158890A (ja) 2019-09-19
EP3257953B1 (en) 2018-09-26
AU2016228188B2 (en) 2018-01-04
KR20180104190A (ko) 2018-09-19
JP2016006426A (ja) 2016-01-14
JP2012520469A (ja) 2012-09-06
US20180356423A1 (en) 2018-12-13
CN113189342B (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
US9933429B2 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
AU2018202110B2 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender- based disease identification, assessment, prevention and therapy
US7888051B2 (en) Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
EP2781913B1 (en) Method for aiding in the diagnosis and therapy of asthma and lung cancer
WO2009039023A2 (en) Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
Long et al. Pattern-based diagnosis and screening of differentially expressed serum proteins for rheumatoid arthritis by proteomic fingerprinting
HK40058647A (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
AU2011351993A1 (en) Protein biomarkers of late stage breast cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181119